CN110577588B - 一种凹耳蛙免疫调节肽及其应用 - Google Patents
一种凹耳蛙免疫调节肽及其应用 Download PDFInfo
- Publication number
- CN110577588B CN110577588B CN201910935233.3A CN201910935233A CN110577588B CN 110577588 B CN110577588 B CN 110577588B CN 201910935233 A CN201910935233 A CN 201910935233A CN 110577588 B CN110577588 B CN 110577588B
- Authority
- CN
- China
- Prior art keywords
- whp
- macrophages
- skin
- fibroblasts
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 24
- 230000007365 immunoregulation Effects 0.000 title abstract description 8
- 241001560070 Rana amurensis Species 0.000 title description 2
- 206010072170 Skin wound Diseases 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 16
- 230000001737 promoting effect Effects 0.000 claims abstract description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 230000035876 healing Effects 0.000 claims description 14
- 230000002519 immonomodulatory effect Effects 0.000 claims description 5
- 241000282414 Homo sapiens Species 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000029663 wound healing Effects 0.000 abstract description 19
- 230000009471 action Effects 0.000 abstract description 3
- 230000007246 mechanism Effects 0.000 abstract description 3
- 210000002950 fibroblast Anatomy 0.000 description 34
- 210000002540 macrophage Anatomy 0.000 description 34
- 210000000440 neutrophil Anatomy 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 210000004979 bone marrow derived macrophage Anatomy 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 15
- 208000027418 Wounds and injury Diseases 0.000 description 14
- 206010052428 Wound Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 241000270959 Pelophylax nigromaculatus Species 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 210000002510 keratinocyte Anatomy 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 230000005012 migration Effects 0.000 description 8
- 238000013508 migration Methods 0.000 description 8
- 102000019034 Chemokines Human genes 0.000 description 7
- 108010012236 Chemokines Proteins 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 230000037319 collagen production Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 102000043136 MAP kinase family Human genes 0.000 description 4
- 108091054455 MAP kinase family Proteins 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 241000269435 Rana <genus> Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 230000035605 chemotaxis Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- DMHGKBGOUAJRHU-UHFFFAOYSA-N Ile-Arg-Pro Natural products CCC(C)C(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O DMHGKBGOUAJRHU-UHFFFAOYSA-N 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 108010016616 cysteinylglycine Proteins 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- -1 pplication Species 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- BRPMXFSTKXXNHF-IUCAKERBSA-N (2s)-1-[2-[[(2s)-pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H]1NCCC1 BRPMXFSTKXXNHF-IUCAKERBSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- TZDNWXDLYFIFPT-BJDJZHNGSA-N Ala-Ile-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O TZDNWXDLYFIFPT-BJDJZHNGSA-N 0.000 description 1
- OEVCHROQUIVQFZ-YTLHQDLWSA-N Ala-Thr-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C)C(O)=O OEVCHROQUIVQFZ-YTLHQDLWSA-N 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- JTKLCCFLSLCCST-SZMVWBNQSA-N Arg-Arg-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N)C(O)=O)=CNC2=C1 JTKLCCFLSLCCST-SZMVWBNQSA-N 0.000 description 1
- OVQJAKFLFTZDNC-GUBZILKMSA-N Arg-Pro-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O OVQJAKFLFTZDNC-GUBZILKMSA-N 0.000 description 1
- NGYHSXDNNOFHNE-AVGNSLFASA-N Arg-Pro-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O NGYHSXDNNOFHNE-AVGNSLFASA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000903210 Bryconamericus alpha Species 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 1
- 102100036189 C-X-C motif chemokine 3 Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- SXJHOPPTOJACOA-QXEWZRGKSA-N Gly-Ile-Arg Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CCCN=C(N)N SXJHOPPTOJACOA-QXEWZRGKSA-N 0.000 description 1
- ZZJVYSAQQMDIRD-UWVGGRQHSA-N Gly-Pro-His Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O ZZJVYSAQQMDIRD-UWVGGRQHSA-N 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- AIPUZFXMXAHZKY-QWRGUYRKSA-N His-Leu-Gly Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O AIPUZFXMXAHZKY-QWRGUYRKSA-N 0.000 description 1
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 1
- 101000947193 Homo sapiens C-X-C motif chemokine 3 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- ATXGFMOBVKSOMK-PEDHHIEDSA-N Ile-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N ATXGFMOBVKSOMK-PEDHHIEDSA-N 0.000 description 1
- IITVUURPOYGCTD-NAKRPEOUSA-N Ile-Pro-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IITVUURPOYGCTD-NAKRPEOUSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- IBMVEYRWAWIOTN-UHFFFAOYSA-N L-Leucyl-L-Arginyl-L-Proline Natural products CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O IBMVEYRWAWIOTN-UHFFFAOYSA-N 0.000 description 1
- ZDJQVSIPFLMNOX-RHYQMDGZSA-N Leu-Thr-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N ZDJQVSIPFLMNOX-RHYQMDGZSA-N 0.000 description 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 1
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 1
- 241001134446 Niveas Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000478335 Odorrana tormota Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- YXHYJEPDKSYPSQ-AVGNSLFASA-N Pro-Leu-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 YXHYJEPDKSYPSQ-AVGNSLFASA-N 0.000 description 1
- 102000049939 Smad3 Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- GTNCSPKYWCJZAC-XIRDDKMYSA-N Trp-Asp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N GTNCSPKYWCJZAC-XIRDDKMYSA-N 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 108010036413 histidylglycine Proteins 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229940035535 iodophors Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108010014614 prolyl-glycyl-proline Proteins 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000003454 tympanic membrane Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及一种免疫调节肽,其包括SEQ ID No.1所示的氨基酸序列。本发明还公开了上述免疫调节肽在制备促进皮肤伤口愈合药物或护肤品中的应用。本发明提供了一种新的免疫调节肽及其应用,并公开了其促进伤口愈合的作用机制,可作为伤口愈合肽模板。
Description
技术领域
本发明涉及医学分子生物学技术领域,尤其涉及一种凹耳蛙免疫调节肽及其应用。
背景技术
伤口愈合是皮肤感染或受到物理创伤后引起的病理过程的总称,需要各种不同类型细胞恢复组织完整性的一个高度有序的生物过程。创面愈合过程涉及几种不同的细胞类型,任何特定细胞类型的细胞活性在修复的不同阶段也可能变化。愈合过程的复杂性和协调性是治疗方法的主要障碍,因此任何治疗剂都必须有效地排序到合适的阶段。伤口愈合作为人体正常的生物过程,是通过四个精确和高度程序化的阶段实现的:止血,炎症,增殖和重塑。伤口愈合是一个动态过程,每个阶段过程中的中断,异常或延长可导致伤口愈合延迟或不愈合的慢性伤口。手术后伤口愈合不良或伤口破裂是外科手术后的常见症状,造成多种不良的预后,包括伤口感染、形成瘢痕等。许多术后感染形成难以愈合性伤口,给患者带来极大的痛苦和心理负担。
在过去的十几年里,各种新型的生物制剂疗法取得了一定的成效,目前可促进伤口愈合的有效药物主要是生长因子类,包括表皮生长因子(EGF),成纤维生长因-2 (FGF-2),血管内皮生长因子 (VEGF),血小板来源的生长因子(PDGF),角质形成细胞因子-1(KGF-1),粒细胞巨噬细胞集落刺激因子 (GM-CSF),粒细胞集落刺激因子(G-CSF)和有一些其他的因子。虽然基于这些生长因子的治疗在临床上取得了一定的应用,但是这些生长因子的分子量大、生产成本很高,从而限制了他们在临床上的广泛应用。
两栖动物的皮肤是有效的天然屏障,在防御、呼吸和水分调节方面起重要作用。由于两栖动物生存环境复杂,其皮肤经常受到各种生物和非生物的损伤,比如捕食、寄生感染、微生物感染和一些物理损伤。然而令人惊奇的是,两栖动物的皮肤即使在没有任何伤后护理情况下仍然具有很好的愈合能力。这说明两栖动物已经进化出优秀的愈合系统,而伤口愈合肽是其重要的组成部分。虽然已有一些两栖动物来源的伤口愈合肽报道,如CN201510000510.3、CN201810366376.2所公开的抗菌肽,但愈合肽的作用机制,比如对伤口处中性粒细胞的趋化作用、对中性粒细胞是否具有直接趋化作用、对巨噬细胞是否具有直接趋化作用、对效应细胞之间互作的调节作用等机制的研究还不够深入。
凹耳蛙多分布于中国安徽省黄山,白天隐匿于阴暗潮湿的洞隙内,夜晚常匍匐在山溪两岸的灌木、矮草枝或草丛的叶片上捕食。由于其鼓膜凹陷,呈一个略向前斜的外听道,科学家多将焦点集中到它的超声通讯以及利用超声通讯的行为学研究上,至今未有生物活性多肽的报道。
发明内容
为解决上述技术问题,本发明的目的是提供一种凹耳蛙免疫调节肽及其应用,本发明提供了一种新的免疫调节肽及其应用,可利用该免疫调节肽作为新型伤口愈合多肽模板。
本发明的第一个目的是公开一种免疫调节肽(以下命名为Ot-WHP),其包括SEQ IDNo.1所示的氨基酸序列。上述Ot-WHP)由24个氨基酸组成,分子量为2666.19道尔顿。
进一步地,免疫调节肽来源于凹耳蛙(拉丁文名为Odorranatormota)。
进一步地,免疫调节肽来源于凹耳蛙的皮肤。
本发明的第二个目的是公开免疫调节肽在制备促进皮肤伤口愈合药物或护肤品中的应用。
进一步地,药物用于促进人类的皮肤伤口愈合。
进一步地,在巨噬细胞存在下,所述药物引起中性粒和巨噬细胞的迁移。
进一步地,药物诱导小鼠巨噬细胞和皮肤伤口处产生趋化因子和细胞因子。
进一步地,药物激活骨髓来源的巨噬细胞的MAPKs、NF-кB和TGF-β/Smad信号通路。
进一步地,在巨噬细胞存在下,所述药物促进角质细胞和成纤维细胞的增殖。
进一步地,在巨噬细胞存在下,所述药物促进成纤维细胞向成纤维母细胞的转化并促进成纤维细胞的胶原产生。
进一步地,在巨噬细胞存在下,所述药物中免疫调节肽的浓度为20-100μg/mL。
借由上述方案,本发明至少具有以下优点:
本发明提供了一种新的免疫调节肽Ot-WHP,其分子量小,生产成本低,将其应用于制备促进皮肤伤口愈合药物中,相比于生长因子而言,应用前景广阔,且其作用机制明确,将来可作为新型的伤口愈合多肽模板。
本发明提供的Ot-WHP可以显著促进小鼠伤口愈合,而且Ot-WHP分子量小,结构简单,易于化学合成和蛋白表达。Ot-WHP作用机制明确,这些优点使其有望成为新一代临床促进伤口愈合的优良候选多肽。
上述说明仅是本发明技术方案的概述,为了能够更清楚了解本发明的技术手段,并可依照说明书的内容予以实施,以下以本发明的较佳实施例并配合详细附图说明如后。
附图说明
图1图示了实施例1中从凹耳蛙皮肤分泌液中分离制备Ot-WHP过程中在 280nm波长下所测得的活性峰;
图2为实施例3中不同实验组小鼠的皮肤伤口愈合情况照片图;
图3为实施例3中不同实验组小鼠的皮肤伤口愈合率测试结果;
图4为实施例4中不同实验组小鼠的中性粒细胞和巨噬细胞的免疫组化和数量统计结果;
图5为实施例5中不同浓度的Ot-WHP对中性粒和巨噬细胞的迁移影响结果;
图6为实施例6中不同浓度的Ot-WHP对小鼠BMDMs细胞和皮肤伤口处的趋化因子和细胞因子产生情况的影响情况测试结果;
图7为实施例7中不同浓度的Ot-WHP对小鼠BMDMs细胞的不同信号通路的激活作用测试结果;
图8为实施例8中不同浓度的Ot-WHP对角质细胞和成纤维细胞的增值影响测试结果;
图9为实施例9中不同浓度的Ot-WHP促进与巨噬细胞协同作用的成纤维细胞向成纤维母细胞的转化以及胶原沉积情况测试结果。
具体实施方式
下面结合实施例,对本发明的具体实施方式作进一步详细描述。以下实施例用于说明本发明,但不用来限制本发明的范围。
实施例1:从凹耳蛙皮肤分泌液中分离制备Ot-WHP
凹耳蛙采集自中国黄山,并用少许乙醚刺激凹耳蛙,会看到蛙体背部有大量分泌液产生,收集分泌液,5000 ×g离心10分钟,收集上清,并冻干。冻干粉溶解于10 mL的PBS中(0.1M,pH6.0),并在5000 ×g离心10分钟,收集上清,上样到Sephadex G-50 (Superfine,Amersham Biosciences,2.6 cm × 100 cm)的葡聚糖凝胶层析柱中,进行过滤层析,过滤层析的缓冲为PBS(0.1M,pH6.0),按照每3mL每10分钟收集一管,约收集200管。收集完毕后,检测各管的在280 nm处的光吸收,根据各管的光吸收值,绘制出图1A。
根据图1A,凹耳蛙皮肤分泌液经Sephadex G-50葡聚糖凝胶过滤层析后,可以被粗分为四个吸收峰,合并各峰,并按照实施例3中检测各峰是否具有促进小鼠皮肤伤口愈合活性,其中发现一个峰具有促进小鼠皮肤伤口愈合的功能(图1A中箭头所示)。然后将图1A中的活性峰上样到C18(5 µm particle size,110 Å pore size,250 mm × 4.6 mm,Gemini,CA,USA)反向高效液相色谱过滤层析,平衡相为加有0.1%三氟乙酸的水,用0-60%的乙腈梯度进行洗脱,洗脱时间为80分钟,检测280 nm处的光吸收,光吸收特征如图1B所示,同上,进行促进皮肤伤口修复活性跟踪,图1B中的活性峰用箭头标出。接着,在和图1B同样的条件下,将图1B中的活性峰进行第二次反向高效液相色谱过滤层析,结果如图1C所示,活性峰用箭头标出,命名为Ot-WHP。
实施例2:Ot-WHP的氨基酸测序
将实施例1中纯化到的Ot-WHP上样到岛津蛋白脉冲液相测序仪(PPSQ-31A;Shimadzu,Kyoto,Japan),按照仪器说明书,进行Edman降解测序,测序完毕后,获得氨基酸序列为ATAWDLGPHGIRPLRPIRIRPLCG(SEQ ID No.1)。
在实际应用过程中,可根据已知的Ot-WHP的氨基酸序列,采用化学合成法直接合成Ot-WHP。
实施例3:Ot-WHP可显著促进小鼠皮肤伤口愈合
实验动物BALB/c小鼠,雌性,6~8周龄,体质量18~20 g,购于上海斯莱克动物有限公司。将小鼠腹腔注射2%的戊巴比妥钠(0.1 mL/20 g)使其麻醉后,用电动剃刀剃去背部毛发后碘伏消毒,在裸露的背部用直径8mm的活检打孔器打一个洞。术后小鼠单独分笼饲养直至实验结束。将小鼠随机分为6组,每组5只,分别为阴性对照组 (20 μL PBS),天然Ot-WHP组(20 μL,200 μg/mL),合成Ot-WHP组 (20 μL,200 μg/mL),乱序Ot-WHP组(SEQ IDNo.2,20 μL,200 μg/mL),AH90阳性多肽对照组(20 μL,200 μg/mL),EGF生长因子对照组(20 μL,100 μg/mL) ,将相应药物分别滴加到对应小鼠伤口处,每天一次,共8天。
结果如图2-3所示,其中图2为术后0,2,4,6,8天拍摄的不同实验组小鼠伤口愈合情况结果;图3A1-A4依次.为术后2,4,6,8天不同实验组小鼠伤口愈合率测试结果。图中,Vehicle代表阴性对照组;synthetic Ot-WHP代表合成Ot-WHP组;NaturalOt-WHP代表天然Ot-WHP组;Scrambled Ot-WHP代表乱序Ot-WHP组。结果表明,天然Ot-WHP和合成Ot-WHP都可以显著促进小鼠皮肤伤口愈合,效果与AH90和EGF相当,而乱序Ot-WHP则没有促进伤口修复的活性。
实施例4:Ot-WHP通过招募中性粒细胞及巨噬细胞迁移至伤口处,加速伤口愈合的炎症起始阶段
按照实施例3的方法处理小鼠,在阴性对照组和天然Ot-WHP组的相应药物分别滴加到对应小鼠伤口处术后指定时间点(0.5,1,2,3天)处死小鼠,取包含伤口中心的活检组织用10%的福尔马林固定,然后通过乙醇脱水,二甲苯清洗,最后石蜡包埋。将石蜡块切成5µm的薄片,经过脱蜡,再水化和抗原修复后进行免疫组化分析。先将切片用5% 的BSA封闭非特异位点,一抗4℃过夜(中性粒细胞的抗体anti-Ly6G,巨噬细胞的抗体anti-F4/80),用辣根过氧化物酶和DBA来免疫显色。中性粒细胞和巨噬细胞的浸润通过统计免疫染色anti-Ly6G和anti-F4/80的细胞数。
结果如图4所示,图4A1-A4分别为不同组小鼠.术后第0.5天和1天招募的中性粒细胞的免疫组化结果,图4C1-C4分别为不同组小鼠.术后第2天和3天招募的巨噬细胞的免疫组化结果,图4B1-B2为不同组小鼠.术后第0.5天和1天招募的中性粒细胞的数量统计结果,图4D1-D2分别为不同组小鼠.术后第2天和3天招募的巨噬细胞的数量统计结果。结果表明,Ot-WHP可促进中性粒细胞及巨噬细胞迁移至伤口处。
实施例5:Ot-WHP不直接引起中性粒和巨噬细胞的迁移,而是需要巨噬细胞的共存才可以引起中性粒和巨噬细胞的迁移
为了明确Ot-WHP如何趋化中性粒细胞和巨噬细胞至伤口局部,将制备好的小鼠中性粒细胞(neutrophils)或骨髓来源的巨噬细胞(BMDMs)重悬于含有2%FBS的RPMI 1640培养基中,细胞密度为7 × 106 cells/mL,吸取100 μL加入到3.0 μm孔径的Transwell小室中(上室,24孔板),然后吸取500 μL的Ot-WHP (25,50,100 μg/mL,Ot-WHP溶解于2% FBS的RPMI 1640培养基中)或培养基(对照)加入到下室中,再在37 ℃细胞培养箱中培养8小时,收集下室中的细胞用血球计数板计数。
在共培养体系中,用2%FBS的RPMI 1640培养基重悬好的小鼠骨髓来源的巨噬细胞(BMDMs,4×106 cells/mL,500 μL)铺于共培养小室的下室(24孔板),待贴壁后,将制备好的小鼠中性粒细胞(neutrophils,7 × 106 cells/mL,100 μL)或骨髓来源的巨噬细胞(BMDMs,7 × 106 cells/mL,100 μL)加入到3.0 μm孔径的Transwell小室中(上室,24孔板),然后吸取500 μL的Ot-WHP (25,50,100 μg/mL,Ot-WHP溶解于2% FBS的 RPMI 1640培养基中)或培养基(对照)加入到下室中,再在37 ℃细胞培养箱中培养8小时,收集上室中的细胞用血球计数板计数,上室中减少的细胞即为迁移的细胞。
结果如图5所示,Ot-WHP在25-100 μg/mL的浓度范围内,并不直接引起中性粒细胞(图5A)和巨噬细胞(图5C)的迁移,但有巨噬细胞共存时,Ot-WHP在25-100 μg/mL的浓度范围内,以剂量依赖的方式,显著引起中性粒细胞(图5B)和巨噬细胞(图5D)的迁移。
实施例6:Ot-WHP可诱导小鼠巨噬细胞和皮肤伤口处产生趋化因子和细胞因子
为了明确为什么在巨噬细胞共存的情况下,Ot-WHP可引起中性粒细胞和巨噬细胞的迁移,将小鼠骨髓来源的巨噬细胞(BMDMs,5×105 cells/well,DMEM培养基,2% FBS)铺于24孔板中,加入Ot-WHP (25,50,100 μg/mL)或等体积的PBS(Vehicle),培养24小时候,收取上清,10000 × g离心10分钟,测趋化因子和细胞因子。
结果如图6A1-A8所示,与Vehicle(PBS,对照)处理组相比,Ot-WHP以剂量依赖的方式,诱导小鼠BMDMs产生趋化因子(CXCL1,CXCL2,CXCL3和CCL2)和细胞因子(TNF-α,IL-1β,IL-6和 TGF-β1)。
然后检测Ot-WHP是否可以诱导小鼠皮肤伤口处产生趋化因子和细胞因子。在指定时间点(第0,0.5,1,2,4和6天)取小鼠的伤口组织,用0.1M的PBS(含1mM的PMSF,1mL/g组织),将伤口组织用玻璃匀浆器进行匀浆。匀浆完成后,12000 × g、4℃离心30分钟,收集上清,测趋化因子(CXCL1和CCL2)和细胞因子(包括TNF-α和 TGF-β1)。
结果如图6B1-B4所示,与Vehicle(PBS,对照)处理组相比,Ot-WHP可有效诱导小鼠皮肤伤口处产生趋化因子(CXCL1和CCL2)和细胞因子(TNF-α和 TGF-β1)。
实施例7:Ot-WHP可激活小鼠骨髓来源的巨噬细胞的MAPKs,NF-кB,TGF-β/Smad信号通路
小鼠骨髓来源的巨噬细胞(BMDMs)接种至6孔板中无血清培养16h。对于MAPKs和NF-κB的检测,BMDMs 与不同浓度的Ot-WHP (0,25,50,100 μg/mL)孵育30min,对于TGF-β/Smad信号通路检测,BMDMs 与不同浓度的Ot-WHP (0,25,50,100 μg/mL)孵育24h 或与100μg/mL Ot-WHP孵育时加或不加TGF-β1的抗体。
结果如图7所示,与Vehicle(PBS,对照)处理组相比,Ot-WHP以剂量依赖的方式激活小鼠BMDMs的MAPKs(ERK,JNK亚基,图7A,7C)、NF-κB(IκBα,p65亚基,图7B,7C)和Smad(Smad2,Smad3,图7D)信号通路,而且Ot-WHP对Smad信号通路的激活是依赖于Ot-WHP诱导的TGF-β的产生(图7E-G)。
实施例8:Ot-WHP不直接促进角质细胞和成纤维细胞增殖,而是需要巨噬细胞的共存才可以促进角质细胞和成纤维细胞的增殖
角质细胞HaCat与小鼠成纤维细胞(5×103cells/well,100 μL/well)接种到96孔板中,与不同浓度的Ot-WHP (25,50,and 100 μg/mL)共同孵育,同时用PBS作对照。HaCat与Ot-WHP孵育24小时后,成纤维细胞与Ot-WHP孵育72小时后,每孔加入细胞计数试剂盒-8(CCK-8)溶液10 µl,37°C继续孵育2-4 h,酶标仪检测450nm处的光吸光值。
对于共培养细胞,HaCat与THP-1来源的巨噬细胞共培养,小鼠成纤维细胞与小鼠巨噬细胞BMDMs共培养。先将HaCat(1×105cells/well)或小鼠成纤维细胞(1×105 cells/well)提前一天接种到24孔板中(下室),待贴壁后,然后在共培养小室(上室)中加入对应的巨噬细胞(1×105 cells/well,100 μL)和不同浓度的Ot-WHP (25,50,100 μg/mL)或Vehicle(PBS,对照)。HaCat与THP-1来源的巨噬细胞共培养24小时后,成纤维细胞与小鼠巨噬细胞BMDMs共培养72小时候后,弃掉共培养的上室,用CCK-8检测下室中的细胞活性。
结果如图8所示,Ot-WHP并不能直接促进角质细胞(图8A)和成纤维细胞(图8B)的增殖;而在巨噬细胞共存的条件下,才可以促进角质细胞(图8C)和成纤维细胞(图8D)的增殖。表明,Ot-WHP可以促进巨噬细胞与角质细胞/成纤维细胞之间的相互作用。
实施例9:Ot-WHP不直接促进成纤维细胞向成纤维母细胞的转化,不直接促进成纤维细胞的胶原产生,而是需要巨噬细胞的共存才可以促进成纤维细胞向成纤维母细胞的转化,才可以促进成纤维细胞的胶原产生
方法同实施例8,用RIPA细胞裂解液,裂解实施例8中处理的成纤维细胞,提取蛋白,用Western blot检测α-SMA的表达,α-SMA表达水平越高,代表成纤维细胞向成纤维母细胞转化的越多);收集实施例8中处理的成纤维细胞的上清,用ELISA试剂盒定量检测上清中胶原的产生情况。
结果如图9所示,Ot-WHP对成纤维细胞α-SMA表达没有直接影响,Ot-WHP不直接促进成纤维细胞向成纤维母细胞的转化(图9A),且Ot-WHP对成纤维细胞胶原生成没有直接影响,不直接促进成纤维细胞的胶原产生(图9B);而是需要巨噬细胞的共存,才可以促进成纤维细胞α-SMA的表达,即促进成纤维细胞向成纤维母细胞的转化(图9C),才可以促进成纤维细胞的胶原产生(图9D)。
以上所述仅是本发明的优选实施方式,并不用于限制本发明,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明技术原理的前提下,还可以做出若干改进和变型,这些改进和变型也应视为本发明的保护范围。
序列表
<110> 苏州大学
<120> 一种凹耳蛙免疫调节肽及其应用
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 24
<212> PRT
<213> (人工序列)
<400> 1
Ala Thr Ala Trp Asp Leu Gly Pro His Gly Ile Arg Pro Leu Arg Pro
1 5 10 15
Ile Arg Ile Arg Pro Leu Cys Gly
20
<210> 2
<211> 24
<212> PRT
<213> (人工序列)
<400> 2
Pro Gly Pro Ile Pro Ala His Leu Gly Arg Arg Trp Ala Ile Leu Ile
1 5 10 15
Arg Pro Asp Leu Thr Arg Cys Gly
20
Claims (3)
1.一种免疫调节肽,其特征在于,其氨基酸序列是SEQ ID No.1所示的氨基酸序列。
2.权利要求1所述的免疫调节肽在制备促进皮肤伤口愈合的药物或护肤品中的应用。
3.根据权利要求2所述的应用,其特征在于:所述药物用于促进人类的皮肤伤口愈合。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910935233.3A CN110577588B (zh) | 2019-09-29 | 2019-09-29 | 一种凹耳蛙免疫调节肽及其应用 |
PCT/CN2020/107720 WO2021057279A1 (zh) | 2019-09-29 | 2020-08-07 | 一种凹耳蛙免疫调节肽及其应用 |
US17/299,472 US11884706B2 (en) | 2019-09-29 | 2020-08-07 | Immunomodulating peptide derived from concave-eared torrent frog and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910935233.3A CN110577588B (zh) | 2019-09-29 | 2019-09-29 | 一种凹耳蛙免疫调节肽及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110577588A CN110577588A (zh) | 2019-12-17 |
CN110577588B true CN110577588B (zh) | 2020-12-29 |
Family
ID=68814028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910935233.3A Active CN110577588B (zh) | 2019-09-29 | 2019-09-29 | 一种凹耳蛙免疫调节肽及其应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US11884706B2 (zh) |
CN (1) | CN110577588B (zh) |
WO (1) | WO2021057279A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110577588B (zh) * | 2019-09-29 | 2020-12-29 | 苏州大学 | 一种凹耳蛙免疫调节肽及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101961493A (zh) * | 2002-06-19 | 2011-02-02 | 大学保健网 | Ace2激活用于治疗心脏、肺和肾脏疾病及高血压 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060159676A1 (en) * | 2005-01-14 | 2006-07-20 | Krieg Paul A | Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions |
CN101333258B (zh) | 2008-07-29 | 2010-09-15 | 辽宁大学 | 一种具有抗菌及促伤口愈合功能的融合多肽 |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CN102657845B (zh) * | 2012-05-31 | 2013-09-11 | 中国科学院昆明动物研究所 | 无指盘臭蛙促皮肤修复多肽ah90和cw49的应用 |
CN110577588B (zh) | 2019-09-29 | 2020-12-29 | 苏州大学 | 一种凹耳蛙免疫调节肽及其应用 |
-
2019
- 2019-09-29 CN CN201910935233.3A patent/CN110577588B/zh active Active
-
2020
- 2020-08-07 WO PCT/CN2020/107720 patent/WO2021057279A1/zh active Application Filing
- 2020-08-07 US US17/299,472 patent/US11884706B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101961493A (zh) * | 2002-06-19 | 2011-02-02 | 大学保健网 | Ace2激活用于治疗心脏、肺和肾脏疾病及高血压 |
Non-Patent Citations (2)
Title |
---|
A0A5J6BS14(A0A5J6BS14_ODOTO);UniProtKB;《UniProtKB》;20191211;A0A5J6BS14_ODOTO * |
WHP precursor [Odorrana tormota];GenBank;《GenBank》;20191016;QEG59350.1 * |
Also Published As
Publication number | Publication date |
---|---|
US11884706B2 (en) | 2024-01-30 |
US20220024998A1 (en) | 2022-01-27 |
WO2021057279A1 (zh) | 2021-04-01 |
CN110577588A (zh) | 2019-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Krummel et al. | Transforming growth factor beta (TGF-β) induces fibrosis in a fetal wound model | |
Granstein et al. | Gamma-interferon inhibits collagen synthesis in vivo in the mouse. | |
CA2721507C (en) | Methods of generating and using procollagen | |
ES2136618T5 (es) | Curacion de heridas. | |
CN108785657B (zh) | 组胺素1多肽在制备促进大面积皮肤缺损修复的复合材料中的应用 | |
CN1083392A (zh) | 用作蛋白质药物释放的含胶原海绵 | |
Sadava et al. | Wound healing process and mediators: Implications for modulations for hernia repair and mesh integration | |
JPH04502923A (ja) | 傷の治癒 | |
CN109641013A (zh) | 包含凝血酶处理干细胞来源的外泌体的皮肤创伤的治疗用组合物 | |
CN110638836A (zh) | 一种水溶性珍珠粉在促进伤口愈合的应用 | |
Samadikuchaksaraei et al. | A dermal equivalent engineered with TGF‐β3 expressing bone marrow stromal cells and amniotic membrane: cosmetic healing of full‐thickness skin wounds in rats | |
CN110577588B (zh) | 一种凹耳蛙免疫调节肽及其应用 | |
CN110903348B (zh) | 一种促进伤口愈合的小肽及其应用 | |
US20130243822A1 (en) | Composition and Method for Healing of Skin Wounds | |
RU2458069C2 (ru) | Выделенный пептид для усиления ранозаживляющей активности кератиноцитов, композиция для заживления ран у млекопитающего и лекарственное средство для применения при заживлении ран у млекопитающего | |
CN112843229B (zh) | 一种促进皮肤损伤修复的药物在整形外科修复中的应用 | |
Behzadi et al. | Amplification of Wound Healing by Propolis and Honey Ointment in Healthy and Diabetic Rat Models; Histopathological and Morphometric Findings | |
CN107446024B (zh) | 一种可拮抗ddx3蛋白rna结合活性的多肽dip-13及其应用 | |
Rudolph et al. | Spatial orientation of microtubules in contractile fibroblasts in vivo | |
CN114716515A (zh) | 一种多肽类似物及其制备方法和应用 | |
CN110935003B (zh) | 促进皮肤损伤修复的生物多肽组合物 | |
CN114644687A (zh) | 一种可拮抗rbm25蛋白rna结合活性的多肽rbip-21及其应用 | |
RU2527701C1 (ru) | Способ приготовления средства, обладающего свойством стимуляции регенерации хрящевой, костной, мышечной тканей и способ стимуляции регенерации хрящевой, костной, мышечной тканей с использованием приготовленного средства | |
CA2839261A1 (en) | Mitigation of cutaneous injury with il-12 | |
CN112675294B (zh) | 一种成纤维细胞的制备及在整形外科修复中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |